Molecular Mechanism of Ginsenoside Rg3 Alleviation in Osteoporosis via Modulation of KPNA2 and the NF-κB Signalling...

Area of Science:

• Molecular Biology
• Cell Biology
• Pharmacology

Background:

• Osteoporosis arises from disrupted bone homeostasis due to imbalanced osteoclast and osteoblast activity.
• Ginsenoside Rg3 (Rg3) shows therapeutic potential for osteoporosis, but its precise molecular mechanisms require further investigation.

Purpose of the Study:

• To elucidate the molecular mechanism by which Rg3 alleviates osteoporosis.
• To investigate the role of karyopherin subunit alpha 2 (KPNA2) in Rg3-mediated effects on osteoclast differentiation.

Main Methods:

• Established an in vitro model using receptor activator of nuclear factor-kappaB ligand (RANKL) to induce osteoclast differentiation in RAW264.7 cells.
• Utilized RNA sequencing to identify differentially expressed genes regulated by Rg3.
• Performed gene knockdown and overexpression experiments, along with pathway inhibition assays (NF-κB inhibitor JSH-23).

Main Results:

• Rg3 treatment downregulated the expression of KPNA2, which was upregulated by RANKL in a time-dependent manner.
• Knockdown of KPNA2 inhibited osteoclast formation and suppressed the nuclear factor kappa-B (NF-κB) pathway.
• KPNA2 overexpression partially reversed the inhibitory effects of Rg3 on osteoclastogenesis, indicating KPNA2 is a target of Rg3 and mediates its action via the NF-κB pathway.

Conclusions:

• Rg3 exerts its anti-osteoporosis effects by inhibiting osteoclast differentiation.
• The mechanism involves the downregulation of KPNA2, which acts as a positive regulator of osteoclast formation through the NF-κB pathway.
• KPNA2 is identified as a key molecular target of Rg3 in the context of osteoporosis treatment.